Increased capacity of lymphocytes to lyse tumor cells in vitro and production of lymphotoxins after cisplatin treatment

Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy

BACKGROUND

Little is known about immune-related radiosensitivity in patients with squamous cell carcinoma of the larynx (SCC-L) treated with radiation therapy (RT).

METHODS

We retrospectively reviewed 91 patients with SCC-L treated with RT or chemoradiation therapy and performed immunohistochemical examination to analyze PD-L1 level on tumor cells, CD4⁺ tumor-infiltrating lymphocytes (TILs), CD8⁺ TIL, and FOXP3⁺ TIL using pretreated biopsy specimens. The association between these immune-related parameters and radiosensitivity was evaluated.

RESULTS

Multivariate analyses showed that high CD8/FOXP3 ratio combined with negative PD-L1 expression was an independent and significant favorable predictive factor for local control, compared with the other groups.

CONCLUSIONS

We showed that high CD8/FOXP3 ratio combined with negative PD-L1 expression might be a useful biomarker of radiosensitivity in patients with SCC-L receiving definitive RT. We propose that coassessment of CD8/FOXP3 ratio and PD-L1 expression level in tumor cells can help predict potential radiosensitivity in patients with SCC-L.

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells

Certain cytotoxic chemotherapeutic drugs are immunogenic, stimulating tumor immunity through mechanisms that are not completely understood. Here we show how the DNA-damaging drug cisplatin modulates tumor immunity. At the maximum tolerated dose (MTD), cisplatin cured 50% of mice with established murine TC-1 or C3 tumors, which are preclinical models of human papillomavirus (HPV)-associated cancer. Notably, the curative benefit of cisplatin relied entirely upon induction of tumor-specific CD8⁺ T cells. Mechanistic investigations showed that cisplatin stimulated tumor infiltration of inflammatory antigen-presenting cells (APC) expressing relatively higher levels of the T-cell costimulatory ligands CD70, CD80, and CD86. Cell death triggered by cisplatin was associated with the release of at least 19 proteins in the tumor environment that could act as damage-associated molecular patterns and upregulate costimulatory molecules, either alone or in concert, but the responsible proteins remain unknown. Essentially, the curative effect of cisplatin was abrogated in mice lacking expression of CD80 and CD86 on APCs. Furthermore, cisplatin treatment was improved by CTLA-4 blockade, which increases the availability of CD80/86 to bind to CD28. In contrast, there was no effect of CD27 stimulation, which replaces CD70 interaction. At the cisplatin MTD, cure rates could also be increased by vaccination with synthetic long peptides, whereas cures could also be achieved at similar rates at 80% of the MTD with reduced side effects. Our findings reveal an essential basis for the immunogenic properties of cisplatin, which are mediated by the induction of costimulatory signals for CD8⁺ T-cell-dependent tumor destruction. Cancer Res; 76(20); 6017-29. ©2016 AACR.

Expression and activation of lyn in macrophages treated in vitro with cisplatin: regulation by kinases, phosphatases and Ca2+/calmodulin

Cisplatin [cis-dichlorodiammine platinum (II)], a potent chemoimmunotherapeutic drug, activates macrophages to tumoricidal state which is inhibited by protein tyrosine kinase(s) inhibitor. Cisplatin induces protein tyrosine phosphorylation of a number of cellular proteins suggesting the involvement of protein tyrosine kinase(s) in the activation process of macrophages. Therefore, the effect of cisplatin treatment on the expression and activation of lyn, a protein tyrosine kinase of src family, in macrophages was investigated. The underlying mechanism of lyn expression and activation was also analyzed. Cisplatin treatment increased lyn expression and activation in macrophages within 5 min of treatment. The expression and activation of lyn were observed to be biphasic processes in cisplatin-treated macrophages with the first peak appearing at 15 min and the second peak at 2 h of treatment. The appearance of second phase of lyn activation and second phase of lyn expression were two unrelated processes. The second peak of lyn activation was produced by the autocrine action of some soluble product(s) of cisplatin-treated macrophages, whereas the second phase of lyn expression was due to some intracellular factor. It was further observed that cisplatin-induced lyn expression and activation involves serine/threonine phosphatases 1/2A, protein tyrosine phosphatases, protein tyrosine kinase and protein kinase C. It was also observed that Ca2+/calmodulin and calmodulin-dependent kinases are involved in the regulation of cisplatin-induced lyn expression and activation in macrophages.

Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial

BACKGROUND

Hepatic arterial infusion of 5-fluoro-2-deoxyuridine (FUdR) is associated with a 60% response rate among previously untreated patients who have hepatic-metastatic colorectal cancer. One obstacle to further dose escalation has been concomitant hepatic toxicity. We are evaluating a FUdR-containing chemotherapeutic emulsion to further dose intensify therapy without associated toxicity.

METHODS

The in vitro pharmacokinetics of the emulsion were determined using high-pressure liquid chromatography (HPLC). The rate at which FUdR is released from emulsion into an overlying aqueous phase was determined in static and dynamic assays. Fifteen patients with hepatic-metastatic colorectal cancer were treated with intrahepatic arterial infusions of emulsion on a phase I dose-escalating clinical protocol. Serum collection determined systemic drug levels using HPLC.

RESULTS

In vitro studies demonstrate that FUdR is slowly released from emulsion into overlying aqueous medium. The emulsion serves as a depot for FUdR. Therapy was well tolerated. Emulsion was sequestered in the liver after infusion in all treated patients.

CONCLUSIONS

This Ethiodol-based, oil-in-water emulsion serves as a sustained-release preparation of FUdR. An Ethiodol-based oil-in-water emulsion is a clinically effective vehicle for delivering FUdR to hepatic-metastatic colorectal tumors.

Effect of in vivo administration of cisplatin on the colony forming ability of murine bone marrow cells

In vitro colony forming ability of bone marrow cells obtained from cisplatin-treated C3H/He mice was studied. Mice were administered cisplatin in a single intraperitoneal dose of 10 mg/kg body wt, 24 h prior to the harvest of femoral bone marrow cells. Incubation of untreated bone marrow cells without any CSF in vitro showed little colony forming ability which was marginally enhanced in cisplatin-treated bone marrow cells. Presence of M-CSF (250 U/ml) or GM-CSF (250 U/ml) in the culture medium significantly augmented the colony forming ability of both untreated and cisplatin-treated bone marrow cells. In the presence of M-CSF, colony forming units-macrophage (CFU-M) were predominantly high in untreated bone marrow cells, followed with CFU-granulocyte-macrophage (CFU-GM). The number of CFU-M was significantly up-regulated in response to M-CSF in bone marrow cells obtained from cisplatin administered mice, whereas the number of CFU-GM remained unchanged, as compared to untreated mice. Both CFU-M and CFU-GM were enhanced in the presence of GM-CSF in untreated bone marrow cells. Cisplatin-treated bone marrow cells on incubation in the presence of GM-CSF showed a significant enhancement of CFU-M and GM as compared to untreated samples. IL-1 (100 U/ml) in the presence of M-CSF significantly up-regulated colony forming ability of cisplatin-treated bone marrow cells, whereas TNF (100 U/ml) inhibited the colony forming ability.(ABSTRACT TRUNCATED AT 250 WORDS)

Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin

The role of cisplatin and FK-565 in up-regulation of lymphokine-activated killer (LAK) cell induction by IL-2 was examined. Treatment of blood mononuclear cells (MNC) of healthy donors with cisplatin or FK-565 in the presence of IL-2 resulted in a significant increase in LAK activity against natural killer (NK)-resistant Daudi cells as assessed by the 4 h 51Cr release assay. Blood MNC treated with cisplatin alone was not cytotoxic to Daudi cells. However, MNC treated with FK-565 showed some cytotoxicity against Daudi cells. Addition of cisplatin to IL-2-stimulated MNC did not increase proliferation but did enhance cytotoxicity. FK-565 together with IL-2 increased both proliferation and cytotoxicity of blood MNC. These data suggest the potential of cisplatin and FK-565 in LAK adoptive immunotherapy for cancer treatment.

In vitro activation of murine bone marrow-derived macrophages with cisplatin and mitomycin-C

Peritoneal macrophages from BALB/c mice after treatment for 24 h in vitro with cisplatin, lipopolysaccharide (LPS) or mitomycin-C were rendered significantly cytotoxic against L-929 tumor target cells. In a similar experiment none of these agents could induce tumoricidal activity of fresh non-adherent bone marrow cells (NABMC). NABMC when incubated in medium alone or in medium containing L-929 culture medium (L-929 CM), a form of macrophage colony stimulating factor (M-CSF), for three days matured to macrophages which were positive for non-specific esterase staining. These bone marrow-derived macrophages cultured with medium alone did not respond to cisplatin. LPS or mitomycin-C for induction of tumoricidal activity whereas bone marrow derived macrophages with that were incubated with L-929 CM showed also significantly enhanced cytotoxicity after treatment with cisplatin, LPS and mitomycin-C. Culturing of NABMC with L-929 CM significantly enhanced cell survival as compared to the cells incubated in medium alone. These results suggest that bone marrow cells not only mature in L-929 CM but also are primed by L-929 CM for induction of tumoricidal activity.

Activation of human NK cells and monocytes with cisplatin in vitro

Human natural killer (NK) cells and monocytes treated in vitro concomitantly with cisplatin and rIFN-gamma enhanced lysis of K562 cells. Lysis was dependent upon the duration of treatment. Cisplatin and rIFN-gamma treated monocytes were equally cytotoxic to NK sensitive (K562) and NK resistant (Daudi & Raji) cell lines whereas NK cells were not rendered cytotoxic against NK resistant tumor cells. NK- and monocyte-mediated cytotoxicity against K562 cells was further enhanced when the effector cells were primed with rIFN-gamma and were subsequently treated with cisplatin.